🚀 VC round data is live in beta, check it out!
OptimizeRx Valuation Multiples
Discover revenue and EBITDA valuation multiples for OptimizeRx and similar public comparables like CareCloud, Findex, CE Holdings, Apiam Animal Health and more.
OptimizeRx Overview
About OptimizeRx
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its product offerings are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.
Founded
2006
HQ
Employees
129
Website
Financials (LTM)
EV
$137M
OptimizeRx Financials
OptimizeRx reported last 12-month revenue of $110M and EBITDA of $24M.
In the same LTM period, OptimizeRx generated $73M in gross profit, $24M in EBITDA, and $19M in net income.
Revenue (LTM)
OptimizeRx P&L
In the most recent fiscal year, OptimizeRx reported revenue of $109M and EBITDA of $24M.
OptimizeRx expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $110M | XXX | $109M | XXX | XXX | XXX |
| Gross Profit | $73M | XXX | $74M | XXX | XXX | XXX |
| Gross Margin | 67% | XXX | 67% | XXX | XXX | XXX |
| EBITDA | $24M | XXX | $24M | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 22% | XXX | XXX | XXX |
| EBIT Margin | 10% | XXX | 11% | XXX | XXX | XXX |
| Net Profit | $19M | XXX | $20M | XXX | XXX | XXX |
| Net Margin | 18% | XXX | 18% | XXX | XXX | XXX |
| Net Debt | — | — | $2M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
OptimizeRx Stock Performance
OptimizeRx has current market cap of $134M, and enterprise value of $137M.
Market Cap Evolution
OptimizeRx's stock price is $7.16.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $137M | $134M | 7.8% | XXX | XXX | XXX | $1.06 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialOptimizeRx Valuation Multiples
OptimizeRx trades at 1.2x EV/Revenue multiple, and 5.7x EV/EBITDA.
EV / Revenue (LTM)
OptimizeRx Financial Valuation Multiples
As of April 18, 2026, OptimizeRx has market cap of $134M and EV of $137M.
Equity research analysts estimate OptimizeRx's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
OptimizeRx has a P/E ratio of 6.9x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $134M | XXX | $134M | XXX | XXX | XXX |
| EV (current) | $137M | XXX | $137M | XXX | XXX | XXX |
| EV/Revenue | 1.2x | XXX | 1.3x | XXX | XXX | XXX |
| EV/EBITDA | 5.7x | XXX | 5.6x | XXX | XXX | XXX |
| EV/EBIT | 11.9x | XXX | 11.4x | XXX | XXX | XXX |
| EV/Gross Profit | 1.9x | XXX | 1.9x | XXX | XXX | XXX |
| P/E | 6.9x | XXX | 6.8x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 7.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified OptimizeRx Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
OptimizeRx Margins & Growth Rates
OptimizeRx's revenue in the last 12 month grew by 4%.
OptimizeRx's revenue per employee in the last FY averaged $0.8M, while opex per employee averaged $0.5M for the same period.
OptimizeRx's rule of 40 is 22% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
OptimizeRx's rule of X is 25% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
OptimizeRx Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | 2% | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 22% | XXX | XXX | XXX |
| EBITDA Growth | 1% | XXX | (6%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 22% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 25% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.8M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 54% | XXX | 54% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 56% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
OptimizeRx Public Comps
See public comps and valuation multiples for other Healthcare Software and Health Data & Analytics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| OptimizeRx | XXX | XXX | XXX | XXX | XXX | XXX |
| CareCloud | XXX | XXX | XXX | XXX | XXX | XXX |
| Findex | XXX | XXX | XXX | XXX | XXX | XXX |
| CE Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| Apiam Animal Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Seer | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
OptimizeRx M&A Activity
OptimizeRx acquired XXX companies to date.
Last acquisition by OptimizeRx was on XXXXXXXX, XXXXX. OptimizeRx acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by OptimizeRx
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialOptimizeRx Investment Activity
OptimizeRx invested in XXX companies to date.
OptimizeRx made its latest investment on XXXXXXXX, XXXXX. OptimizeRx invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by OptimizeRx
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout OptimizeRx
| When was OptimizeRx founded? | OptimizeRx was founded in 2006. |
| Where is OptimizeRx headquartered? | OptimizeRx is headquartered in United States. |
| How many employees does OptimizeRx have? | As of today, OptimizeRx has over 129 employees. |
| Who is the CEO of OptimizeRx? | OptimizeRx's CEO is Stephen L. Silvestro. |
| Is OptimizeRx publicly listed? | Yes, OptimizeRx is a public company listed on Nasdaq. |
| What is the stock symbol of OptimizeRx? | OptimizeRx trades under OPRX ticker. |
| When did OptimizeRx go public? | OptimizeRx went public in 1996. |
| Who are competitors of OptimizeRx? | OptimizeRx main competitors are CareCloud, Findex, CE Holdings, Apiam Animal Health. |
| What is the current market cap of OptimizeRx? | OptimizeRx's current market cap is $134M. |
| What is the current revenue of OptimizeRx? | OptimizeRx's last 12 months revenue is $110M. |
| What is the current revenue growth of OptimizeRx? | OptimizeRx revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of OptimizeRx? | Current revenue multiple of OptimizeRx is 1.2x. |
| Is OptimizeRx profitable? | Yes, OptimizeRx is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of OptimizeRx? | OptimizeRx's last 12 months EBITDA is $24M. |
| What is OptimizeRx's EBITDA margin? | OptimizeRx's last 12 months EBITDA margin is 22%. |
| What is the current EV/EBITDA multiple of OptimizeRx? | Current EBITDA multiple of OptimizeRx is 5.7x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.